Skip to main content

Advertisement

SpringerLink
Log in

Galantamine Extended Release in Alzheimer’s Disease

Profile Report

  • Adis Profile Report
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement. In the US, the trade name Reminyl® has been changed to Razadyne™ to avoid confusion with the diabetes drug Amaryl®.[10]

References

  1. Robinson DM, Plosker GL. Galantamine extended release. CNS Drugs 2006; 20(8): 673–81

    Article  PubMed  CAS  Google Scholar 

  2. Farlow MR. Galantamine extended release: a viewpoint by Martin R. Farlow. CNS Drugs 2006; 20(8): 682

    Article  Google Scholar 

  3. Jann MW. Galantamine extended release: a viewpoint by Michael W. Jann. CNS Drugs 2006; 20(8): 682–3

    Article  Google Scholar 

  4. Lyketsos CG, Kozauer NA. Galantamine extended release: a viewpoint by Constantine G. Lyketsos and Nicholas A. Kozauer. CNS Drugs 2006; 20(8): 683

    Article  Google Scholar 

  5. Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003 Mar 4; 138(5): 400–10

    PubMed  Google Scholar 

  6. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med 2003 Apr 3; 348(14): 1356–64

    Article  PubMed  CAS  Google Scholar 

  7. Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000 Jul 25; 55(2): 198–204

    Article  PubMed  CAS  Google Scholar 

  8. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005 Dec 17; 366(9503): 2112–7

    Article  PubMed  Google Scholar 

  9. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer’s disease. Drugs 2000 Nov; 60(5): 1095–122

    Article  PubMed  CAS  Google Scholar 

  10. Ortho-McNeil Neurologics Inc. Reminyl® (galantamine hydrobromide) renamed Razadyne™ (galantamine hydrobromide) in U.S. to support patient safety [online]. Available from URL: http://www.jnj.com [Accessed 2006 Mar 15]

  11. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–39

    Article  PubMed  CAS  Google Scholar 

  12. Zhao Q, Janssens L, Verhaeghe T, et al. Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers. Curr Med Res Opin 2005 Oct; 21(10): 1547–54

    Article  PubMed  CAS  Google Scholar 

  13. Brodaty H, Corey-Bloom J, Potocnik FCV, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 20(2): 120–32

    Article  PubMed  CAS  Google Scholar 

  14. Lyketsos CG, Colenda C, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patient’s with dementia due to Alzheimer’s disease. Am J Ger Psychiatry 2006 Jul; 14(7): 561–72

    Article  Google Scholar 

  15. Rabins PV, Lyketsos C, Steele C. Practical dementia care. 2nd ed. New York: Oxford University Press, 2006

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wolters Kluwer Health | Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    Dean M. Robinson & Greg L. Plosker

  2. editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

    Dean M. Robinson & Greg L. Plosker

Authors
  1. Dean M. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Greg L. Plosker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dean M. Robinson.

Additional information

Adapted and reproduced from CNS Drugs 2006; 20 (7): 673–83.[1–4] The manufacturer of the agent under review was offered an opportunity to comment on the original article[1] during the peer review process; changes based on any comments received were made on the basis of scientific and editorial merit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, D.M., Plosker, G.L. Galantamine Extended Release in Alzheimer’s Disease. Drugs Aging 23, 839–842 (2006). https://doi.org/10.2165/00002512-200623100-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200623100-00006

Keywords

Search

Navigation